RT Journal Article
SR Electronic
T1 Olmesartan Reduces Microalbuminuria in Patients with Type 2 Diabetes
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 5
SP 9
OP 10
DO 10.1177/155989771005007
UL http://mdc.sagepub.com/content/10/5/9.2.abstract
AB Early treatment with the angiotensin receptor blocker (ARB) olmesartan significantly reduced the risk of developing microalbuminuria among patients with type 2 diabetes, according to new interim findings from the ongoing Randomized Olmesartan and Diabetes Microalbuminuria Prevention [ROADMAP] trial. However, olmesartan also appeared to increase the risk of cardiovascular mortality, raising concerns about the safety of ARBs in this patient population.